(Sharecast News) - AstraZeneca said on Thursday that it will pay up to $1.86bn to enter a new strategic drug discovery collaboration and licensing agreement with Califiornia-based AI biotech firm Insitro.
The collaboration will identify novel drug targets and advance the design of new therapeutics for patients for metabolic dysfunction-associated steatohepatitis...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE